Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops precision oncology medicines. The company's lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1/2 for use in the treatment of platinum-resistant ovarian cancer; endometrial and bladder cancer; and SCCs, including SCCHN, cervical, and anal cancer. It is also developing two preclinical drug programs used to predict tumor sensitivity based on custom OncoSignature tests. The company was incorporated in 2018 and is based in Watertown, Massachusetts.